Covid jab 競争相手s 直面する off in 法廷，裁判所 as US 会社／堅い Moderna 告訴するs Pfizer and BioNTech for '（規則などを）破る／侵害するing on its 特許' for life-saving mRNA ワクチンs

  • The 裁判，公判 is 推定する／予想するd to last three and a half weeks at the High 法廷，裁判所 in London?

By Lettice Bromovsky

Published: | Updated:

Covid-19 jab 競争相手s 直面する off in 法廷，裁判所 today as a weeks-long 裁判，公判 begins over an 違反 on the life-saving ワクチン 科学（工学）技術's 特許.

製薬の 巨大（な） Pfizer and 麻薬 製造業者 BioNTech are locked in a 合法的な 論争 with ワクチン 製造者 Moderna?at the High 法廷，裁判所 in London over the use of messenger リボ核酸 (mRNA) 科学（工学）技術 in coronavirus jabs まっただ中に 平行の litigation in the US, Germany, the Netherlands?and other countries.

Moderna said in 2020 that it would not 施行する its Covid-19 関係のある 特許s while the pandemic continued.

But the company said in March 2022, with ワクチン 供給（する）s 改善するing globally, that it was updating the 誓約（する） and 推定する／予想するd its 知識人 所有物／資産／財産 to be 尊敬（する）・点d in 非，不，無-low and middle-income countries where 供給（する） was no longer a 障壁 to 接近.

Now Moderna is 告訴するing American competitor Pfizer and its German partner BioNTech for 申し立てられた／疑わしい 特許 違反 in relation to their Comirnaty ワクチン, arguing it is 予定 補償（金） for 製品s 製造（する）d after March 7 2022.

Moderna is suing American competitor Pfizer and its German partner BioNTech for alleged patent infringement in relation to their Comirnaty vaccine,?arguing it is due compensation for products manufactured after March 7 2022

Moderna is 告訴するing American competitor Pfizer and its German partner BioNTech for 申し立てられた／疑わしい 特許 違反 in relation to their Comirnaty ワクチン,?arguing it is 予定 補償（金） for 製品s 製造（する）d after March 7 2022

Employees working at the Pfizer factory.?Moderna said in 2020 that it would not enforce its Covid-19 related patents while the pandemic continued

従業員s working at the Pfizer factory.?Moderna said in 2020 that it would not 施行する its Covid-19 関係のある 特許s while the pandemic continued

London High Court (above). But the company said in March 2022, with vaccine supplies improving globally, that it was updating the pledge and expected its intellectual property to be respected in non-low and middle-income countries where supply was no longer a barrier to access

London High 法廷，裁判所 (above). But the company said in March 2022, with ワクチン 供給（する）s 改善するing globally, that it was updating the 誓約（する） and 推定する／予想するd its 知識人 所有物／資産／財産 to be 尊敬（する）・点d in 非，不，無-low and middle-income countries where 供給（する） was no longer a 障壁 to 接近

Pfizer and BioNTech have 否定するd 違反 with both 会社／堅いs 捜し出すing the 'revocation' of two Moderna 特許s, （人命などを）奪う，主張するing that they are '無効の'.

An 推定する／予想するd three-and-a-half week 裁判，公判 before 裁判官 Mr 司法（官） Meade started on Tuesday 焦点（を合わせる）ing on one of the 特許s at the heart of the 合法的な 論争.

The second 特許 is 推定する／予想するd to be considered next week, when there is also 推定する／予想するd to be a linked 審理，公聴会 before a different 裁判官 for arguments over Moderna's '特許 誓約（する）'.

Tom Mitcheson KC, 代表するing Pfizer and BioNTech, said in written arguments that Moderna was 捜し出すing 損害賠償金 but not 捜し出すing a 法廷，裁判所 （裁判所の）禁止（強制）命令 予定 to it 'recognising the public 利益／興味 in the continued availability of the Comirnaty 範囲 of ワクチンs'.

He said the challenge over the 有効性，効力 of one of the 特許s centred on an 申し立てられた／疑わしい '欠如（する） of novelty' in relation to work done by Katalin Kariko and Drew Weissman when at the University of Pennsylvania in the US.

The pair won the 2023 Nobel Prize in 薬／医学 for 発見s that were '批判的な for developing 効果的な mRNA ワクチンs against Covid-19 during the pandemic', the 法廷，裁判所 was told.

The second patent is expected to be considered next week, when there is also expected to be a linked hearing before a different judge for arguments over Moderna's 'patent pledge'

The second 特許 is 推定する／予想するd to be considered next week, when there is also 推定する／予想するd to be a linked 審理，公聴会 before a different 裁判官 for arguments over Moderna's '特許 誓約（する）'

Pfizer's vaccines during manufacture.?Tom Mitcheson KC, representing Pfizer and BioNTech, said in written arguments that Moderna was seeking damages but not seeking a court injunction due to it 'recognising the public interest in the continued availability of the Comirnaty range of vaccines'

Pfizer's ワクチンs during 製造（する）.?Tom Mitcheson KC, 代表するing Pfizer and BioNTech, said in written arguments that Moderna was 捜し出すing 損害賠償金 but not 捜し出すing a 法廷，裁判所 （裁判所の）禁止（強制）命令 予定 to it 'recognising the public 利益／興味 in the continued availability of the Comirnaty 範囲 of ワクチンs'

Mr Mitcheson said that 'it is （疑いを）晴らす that even on Moderna's 事例／患者 the difference between the 事前の art and the 特許 is wafer thin'.

Piers Acland KC, fo r Moderna, said in written submissions that the 競争相手 developers' arguments were 'not 信頼できる', 追加するing: 'It does no disservice to Professors Kariko and Weissman's 驚くべき／特命の／臨時の 出資／貢献s to 認める Moderna's 驚くべき／特命の／臨時の 出資／貢献 too.'

Moderna's Spikevax ワクチン was the third jab to be 認可するd for use in the UK in January 2021 after the Pfizer/BioNTech and Oxford/AstraZeneca ワクチンs were 認可するd.

How the Moderna and Pfizer/BioNTech ワクチンs work is by 的ing the spike protein in Covid-19 which the ウイルス uses to enter human 独房s.

The Moderna and Pfizer/BioNTech ワクチンs use synthetic messenger リボ核酸 (mRNA), a genetic 構成要素 that 含む／封じ込めるs （警察などへの）密告，告訴（状） about the spike protein.

The ワクチンs 供給する the 団体／死体 with 指示／教授／教育s to produce a small 量 of this protein which, once （悪事，秘密などを）発見するd by the 免疫の system, leads to a 保護の antibody 返答.

The 裁判，公判 continues.

ModernaPfizerGermanyThe Netherlands